Monogenic autoinflammatory diseases: Cytokinopathies
Introduction
In the decade since Hawkins, Lachmann and McDermott described the remarkable efficacy of recombinant human interleukin-1–receptor antagonist anakinra in the treatment of a patient with Muckle–Wells Syndrome [1], the prognosis of patients with cryopyrin-associated periodic fever syndromes (CAPS) has changed dramatically. Prior to the elucidation of IL-1 signalling in CAPS, non-specific immunosuppressive medications were trialled with a relatively poor response. Once the genetic basis was shown to be mutations in NLRP3, the gene encoding cryopyrin [2], the dominant role of IL-1 in CAPS was established and the theoretical and subsequent practical benefit of anakinra confirmed. Since this time, there has been a focus on determining the genetic basis of inflammatory diseases in general, and exploring potential benefit of biologic agents. Here, we categorise and use monogenic autoinflammatory diseases to illuminate cytokine pathways, and highlight the complexity and areas of uncertainty in the pathophysiology of these diseases (Fig. 1).
Section snippets
IL-1
The role of the IL-1 family in innate and adaptive immunity has been well explored. A total of 11 members have been identified, whose various effects are mediated via four signal receptor complexes and two decoy receptors [3], [4].
The first of these cytokines, IL-1, has many and widespread biological functions including mediation of inflammatory and acute phase responses. The inactive precursor to IL-1β (pro-IL-1β) is found predominantly in the cytoplasm of haematopoietic cells and is produced
IL-36
The IL-36 cytokines, comprising of IL-36α, IL-36β and IL-36γ, are part of the IL-1 family, agonists exhibiting proinflammatory effects via the IL-36R (IL-1Rrp2) [4], [47]. Once released, IL-36 cytokines lead to a number of factors that induce Th1 and Th17 polarisation [4], [47]. Whilst initially thought to be primarily produced by innate immune cells and lymphocytes, there is evidence of its release from epithelial cells in the skin and lungs as well as brain tissue [47]. Interestingly, despite
IL-10
IL-10 is widely produced by many immune cells and displays potent anti-inflammatory effects [57], [58], [59], [60]. The function of this cytokine is complex, and depends on the cell type on which it is acting [58], [59], [60].
Interferons
Interferons have a variety of effects with well described antiviral, antitumor and immunomodulatory activity. Type I interferons (IFN-α, -β, -ω, -ε, -κ) are produced by most cells, whereas NK, NKT and T cells are the primary sources of type II interferons (IFN-γ) [64]. Type I and type II interferon receptor components (IFNAR1/2 and IFNG1/2 respectively) are expressed on most nucleated cells, suggesting that both have the potential for widespread activity [64].
Multiple cytokines
Not all monogenic autoinflammatory syndromes have their mechanisms linked to one cytokine alone. Despite this, pleiotropic cytokinopathies tend to have a single well defined defect in physiology and can respond remarkably well to targeted therapy.
Not yet known
Two recently described autoinflammatory conditions involve the PLCγ2. PLCγ2-associated antibody deficiency and immune dysregulation (PLAID) is characterised by cold induced urticaria, granulomatous disease, autoimmune disease and hypogammaglobulinemia [116], [117]. Patients with this condition have an autosomal dominant inframe deletion in PLCG2 resulting in gain of function of PLCγ2 and increased PLCγ2-dependent signalling after receptor crosslinking [116], [117]. Chronic stimulation and
Conclusion
The recent description of unusual phenotypes with features of autoinflammation as well as autoimmunity has blurred the distinction between the two classes of syndromes and has highlighted the intimate link between innate and adaptive immune responses. Furthermore, diseases limited to specific organ systems suggest that autoinflammation need not be systemic. The response to targeted treatment is profound in patients where the specific cytokine involved can be identified. For this reason, it is
References (125)
- et al.
The interleukin-1 family: back to the future
Immunity
(2013) - et al.
Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals
Clin Immunol
(2010) NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder
Immunity
(2004)Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis
Mol Cell
(2003)Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity
Mol Cell
(2013)INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation
J Biol Chem
(2004)- et al.
Autoinflammatory bone diseases
Rheum Dis Clin North Am
(2013) Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome
J Allergy Clin Immunol
(2010)Schnitzler’s syndrome improvement after anti-TNF-alpha therapy
Joint Bone Spine
(2010)Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome
J Allergy Clin Immunol
(2012)